Review





Similar Products

human cd6 clone 5a10a2 ma5-38488 antibody  (Thermo Fisher)
90
Thermo Fisher human cd6 clone 5a10a2 ma5-38488 antibody
Itolizumab increased the tumor cell killing capacity of PBMC by blocking the inhibitory effects associated with <t>CD6-CD318</t> interaction. (A) PBMC and MDA-MB-231, NCI-H460, SKOV-3 and HCT-116 cell lines (n=4) were pre-incubated with 10 µg/mL of isotype control (IC, green), itolizumab (T1h, blue), or neutralizing antibodies specific for CD318 (brown) or ALCAM (yellow). Effector and target cells were then co-cultured, and tumor cell lysis was measured using 7AAD staining by flow cytometry. (B) CFSE-labeled T-cells (n=6) were activated with antiCD3/CD28 beads and incubated with 10ug/mL of pre-coated human recombinant CD318 (brown), ALCAM (yellow), or PBS (green) as control. (C) Immune cell viability was measured on isotype control treated-PBMC co-cultured with human tumor cell lines MDA-MB-231 (n=10, red) and MCF-7 (n=10, green) using flow cytometry. Representative histograms or dot plots for each condition, and individual viability percentage and CFSE dilution are displayed. Data are depicted as median ± 95% confidence interval. Statistical analysis was performed using the Kruskal-Wallis test and Dunn’s multiple comparisons test with unpaired data. Only statistical significance is shown in the graphs, with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.
Human Cd6 Clone 5a10a2 Ma5 38488 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd6 clone 5a10a2 ma5-38488 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
human cd6 clone 5a10a2 ma5-38488 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Itolizumab increased the tumor cell killing capacity of PBMC by blocking the inhibitory effects associated with CD6-CD318 interaction. (A) PBMC and MDA-MB-231, NCI-H460, SKOV-3 and HCT-116 cell lines (n=4) were pre-incubated with 10 µg/mL of isotype control (IC, green), itolizumab (T1h, blue), or neutralizing antibodies specific for CD318 (brown) or ALCAM (yellow). Effector and target cells were then co-cultured, and tumor cell lysis was measured using 7AAD staining by flow cytometry. (B) CFSE-labeled T-cells (n=6) were activated with antiCD3/CD28 beads and incubated with 10ug/mL of pre-coated human recombinant CD318 (brown), ALCAM (yellow), or PBS (green) as control. (C) Immune cell viability was measured on isotype control treated-PBMC co-cultured with human tumor cell lines MDA-MB-231 (n=10, red) and MCF-7 (n=10, green) using flow cytometry. Representative histograms or dot plots for each condition, and individual viability percentage and CFSE dilution are displayed. Data are depicted as median ± 95% confidence interval. Statistical analysis was performed using the Kruskal-Wallis test and Dunn’s multiple comparisons test with unpaired data. Only statistical significance is shown in the graphs, with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.

Journal: Frontiers in Immunology

Article Title: Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines

doi: 10.3389/fimmu.2025.1585597

Figure Lengend Snippet: Itolizumab increased the tumor cell killing capacity of PBMC by blocking the inhibitory effects associated with CD6-CD318 interaction. (A) PBMC and MDA-MB-231, NCI-H460, SKOV-3 and HCT-116 cell lines (n=4) were pre-incubated with 10 µg/mL of isotype control (IC, green), itolizumab (T1h, blue), or neutralizing antibodies specific for CD318 (brown) or ALCAM (yellow). Effector and target cells were then co-cultured, and tumor cell lysis was measured using 7AAD staining by flow cytometry. (B) CFSE-labeled T-cells (n=6) were activated with antiCD3/CD28 beads and incubated with 10ug/mL of pre-coated human recombinant CD318 (brown), ALCAM (yellow), or PBS (green) as control. (C) Immune cell viability was measured on isotype control treated-PBMC co-cultured with human tumor cell lines MDA-MB-231 (n=10, red) and MCF-7 (n=10, green) using flow cytometry. Representative histograms or dot plots for each condition, and individual viability percentage and CFSE dilution are displayed. Data are depicted as median ± 95% confidence interval. Statistical analysis was performed using the Kruskal-Wallis test and Dunn’s multiple comparisons test with unpaired data. Only statistical significance is shown in the graphs, with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.

Article Snippet: Human CD6 (clone 5A10A2, MA5‐38488, ThermoFisher, USA) and CD318 (polyclonal, ab1377, Abcam, USA) specific mouse mAbs were used for immunohistochemical (IHC) evaluations.

Techniques: Blocking Assay, Incubation, Control, Cell Culture, Lysis, Staining, Flow Cytometry, Labeling, Recombinant

CD6-CD318 interaction induced CD6 downmodulation. Isotype control treated PBMC were co-cultured with human tumor cell lines MDA-MB-231 (red), NCI-H460 (orange), and MCF-7 (green). CD6 loss was measured on PBMC (n=6) using flow cytometry. (A) Representative histograms of CD6 expression and individual values of CD6 MFI on isotype control treated PBMC challenged with tumor cell lines. (B) Representative histograms of CD6 expression on isotype control treated CD4+ and CD8+ T-cells and NK (CD56+) cells challenged with tumor cell lines. (C) Representative histograms and frequencies of CD6+ cells on isotype control treated PBMC challenged with tumor cell lines and co-cultured in a modified Boyden chamber with a transwell membrane of 0.4μm. Data are represented as median ± 95% confidence interval. Statistical analysis was performed using one-way ANOVA with unpaired data and Tuckey’s multiple comparison test. Only statistical significance is shown in the graphs, with ***p ≤ 0.001, and ****p ≤ 0.0001. ( D). Representative IHC staining with CD318 and CD6 in breast tumor tissue samples (n 117) and relation of patients with low/negative, intermediate, and high staining scores for both molecules. ( E). Pearson’s correlation analysis of CD318 expression and CD6+ infiltrated on breast tumor tissue samples by IHC.

Journal: Frontiers in Immunology

Article Title: Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines

doi: 10.3389/fimmu.2025.1585597

Figure Lengend Snippet: CD6-CD318 interaction induced CD6 downmodulation. Isotype control treated PBMC were co-cultured with human tumor cell lines MDA-MB-231 (red), NCI-H460 (orange), and MCF-7 (green). CD6 loss was measured on PBMC (n=6) using flow cytometry. (A) Representative histograms of CD6 expression and individual values of CD6 MFI on isotype control treated PBMC challenged with tumor cell lines. (B) Representative histograms of CD6 expression on isotype control treated CD4+ and CD8+ T-cells and NK (CD56+) cells challenged with tumor cell lines. (C) Representative histograms and frequencies of CD6+ cells on isotype control treated PBMC challenged with tumor cell lines and co-cultured in a modified Boyden chamber with a transwell membrane of 0.4μm. Data are represented as median ± 95% confidence interval. Statistical analysis was performed using one-way ANOVA with unpaired data and Tuckey’s multiple comparison test. Only statistical significance is shown in the graphs, with ***p ≤ 0.001, and ****p ≤ 0.0001. ( D). Representative IHC staining with CD318 and CD6 in breast tumor tissue samples (n 117) and relation of patients with low/negative, intermediate, and high staining scores for both molecules. ( E). Pearson’s correlation analysis of CD318 expression and CD6+ infiltrated on breast tumor tissue samples by IHC.

Article Snippet: Human CD6 (clone 5A10A2, MA5‐38488, ThermoFisher, USA) and CD318 (polyclonal, ab1377, Abcam, USA) specific mouse mAbs were used for immunohistochemical (IHC) evaluations.

Techniques: Control, Cell Culture, Flow Cytometry, Expressing, Modification, Membrane, Comparison, Immunohistochemistry, Staining